Date Title Description PDF
24 Feb 2021 About corporate governance The Company informs about the agreements adopted by the Board of Directors  Download
27 Nov 2020 On business and financial situation The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia Download
09 Jul 2020 On business and financial situation ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate Download

Pages

Date Title Description PDF
08 May 2025 Announcement of General Shareholders’ Meeting The Company announces the call of its 2025 Ordinary General Shareholders' Meeting Download
04 Apr 2025 Liquidity and counterparty agreements Liquidity contract: transactions conducted in the first quarter of 2025 Download
25 Feb 2025 Annual Financial Reports and Audit Reports The Company submits the 2024 Annual Financial Report  Download
25 Feb 2025 Annual Report regarding remuneration of the members of the Board of Directors ROVI releases the 2024 annual report regarding remuneration of the members of the Board of Directors Download
07 Jan 2025 Liquidity and counterparty agreements Liquidity contract: transactions conducted in the fourth quarter of 2024 Download

Pages

Date Title Description PDF
05 Oct 2017 Contratos de liquidez y contrapartida Liquidity contract: modification of transactions conducted from 11 July to 30 September 2017. Download
03 Oct 2017 Contratos de liquidez y contrapartida Liquidity contract: transactions conducted from 11 July to 30 September 2017   Download
07 Sep 2017 Otros sobre negocio y situación financiera The Company informs that commences the enoxaparin biosimilar marketing in Germany Download
26 Jul 2017 Información sobre resultados ROVI releases the presentation related to the 2017 first half results Download
26 Jul 2017 Información sobre resultados ROVI releases the presentation related to the 2017 first half results Download

Pages